KBI Biopharma, Inc., a JSR Life Sciences company, launched SUREmAb, an offering built on KBI’s SUREtechnology Platform designed for optimized, safe, and cost-efficient monoclonal antibody (mAb) development and manufacturing.

SUREmAb is a vertically integrated global offering designed to minimize development timelines for global biopharmaceutical manufacturers, delivering research cell bank (RCB) development in as little as nine weeks and the ability for customers to move from DNA to GMP drug substance in as few as 11 months, according to the company. In addition, SUREmAb is engineered to achieve titers of up to 10 g/L with a lower-cost workflow to optimize operational efficiency and maximize ROI.

According to the company, the operational consolidation of KBI Biopharma and Selexis, played an important role in the operations that power the SUREmAb technology, enabling KBI to streamline processes and offer greater efficiencies in monoclonal antibody development and manufacturing.

“SUREmAb represents not just the culmination of decades of biologics production expertise but our vision for the future of mAb development,” said KBI chief scientific officer, Sigma Mostafa. “In an era where time, efficiency, and innovation converge, we’re proud to introduce a platform that can not only accelerate the development journey but is high quality and cost-effective, from the start. At KBI, we believe in anticipating market shifts and pioneering solutions that address tomorrow’s challenges today, and SUREmAb is a testament to that commitment.”

“We recognize the need to be a strong partner for customers with novel therapies so that they have the best chance of reaching as many patients as possible,” said KBI CEO, J.D. Mowery. “The simplified access to SUREmAb and ongoing manufacturing with KBI shows our commitment to supporting the industry by improving a key barrier to development.”